JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $24

Benzinga · 05/10 16:34
JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $25 to $24.